Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

5,222 shares were sold on June 8, 2026 for approximately $143,000 at a weighted average price of about $27.30 per share. The article is a straightforward insider transaction disclosure with no additional operational or financial context. The sale is modest in size and is unlikely to materially affect the stock.

Analysis

5,222 shares were sold on June 8, 2026 for approximately $143,000 at a weighted average price of about $27.30 per share. The article is a straightforward insider transaction disclosure with no additional operational or financial context. The sale is modest in size and is unlikely to materially affect the stock.